Patrick Badertscher

Patrick Badertscher

Auto-generated profile, based on publicly available information

Patrick Badertscher

Department of Cardiology, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
DMDiego Mannhart
Diego Mannhart
MLMirko Lischer
Mirko Lischer
SKSven Knecht
Sven Knecht
JLJeanne du Fay de Lavallaz
Jeanne du Fay de Lavallaz
ISIvo Strebel
Ivo Strebel
PBPatrick Badertscher
Patrick Badertscher

30 November 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
PBPatrick Badertscher
Patrick Badertscher
SWSimon Weidlich
Simon Weidlich
SKSven Knecht
Sven Knecht
NSNiklas Stauffer
Niklas Stauffer
PKPhilipp Krisai
Philipp Krisai
MKMichael Kühne
Michael Kühne
Pulsed-field ablation (PFA) has emerged as a novel treatment technology for patients with atrial fibrillation (AF). Cryoballoon (CB) is the most frequently used single shot technology. A direct comparison to a novel CB system is lacking. We aimed to compare pulmonary vein isolation (PVI) using PFA vs. a novel CB system regarding efficiency, safety, myocardial injury, and outcomes. One hundred and eighty-one consecutive patients underwent PVI and were included (age 64 ± 9.7 years, ejection fraction 0.58 ± 0.09, left atrial size 40 ± 6.4 mm, paroxysmal AF 64%). 106 patients (59%) underwent PFA (FARAPULSE, Boston Scientific) and 75 patients (41%) underwent CB ablation (PolarX, Boston Scientific). The median procedure time, left atrial dwell time and fluoroscopic time were similar between the PFA and the CB group with 55 [interquartile range (IQR) 43–64] min vs. 58 (IQR 48–69) min (P < 0.087), 38 (30–49) min vs. 37 (31–48) min, (P = 0.871), and 11 (IQR 9.3–14) min vs. 11 (IQR 8.7–16) min, (P < 0.81), respectively. Three procedural complications were observed in the PFA group (two tamponades, one temporary ST elevation) and three complications in the CB group (3× reversible phrenic nerve palsies). During the median follow-up of 404 days (IQR 208–560), AF recurrence was similar in the PFA group and the CB group with 24 vs. 30%, P = 0.406. Procedural characteristics were very similar between PFA and CB in regard to procedure duration fluoroscopy time and complications. Atrial fibrillation free survival did not differ between the PFA and CB groups. Comparison between pulsed field ablation and cryoballoon PolarX. AF, atrial fibrillation.

2 November 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
TSTeodor Serban
Teodor Serban
DMDiego Mannhart
Diego Mannhart
QAQurrat-Ul-Ain Abid
Qurrat-Ul-Ain Abid
AHAndres Höchli
Andres Höchli
SLSorin Lazar
Sorin Lazar
PBPatrick Badertscher
Patrick Badertscher
Aims: Pulmonary vein isolation (PVI) plays a central role in the interventional treatment of atrial fibrillation (AF). Uncertainties remain about the durability of ablation lesions from different energy sources. We aimed to systematically review the durability of ablation lesions associated with various PVI-techniques using different energy sources for the treatment of AF. Methods and results: Structured systematic database search for articles published between January 2010 and January 2023 reporting PVI-lesion durability as evaluated in the overall cohort through repeat invasive remapping during follow-up. Studies evaluating only a proportion of the initial cohort in redo procedures were excluded. A total of 19 studies investigating 1050 patients (mean age 60 years, 31% women, time to remap 2–7 months) were included. In a pooled analysis, 99.7% of the PVs and 99.4% of patients were successfully ablated at baseline and 75.5% of the PVs remained isolated and 51% of the patients had all PVs persistently isolated at follow-up across all energy sources. In a pooled analysis of the percentages of PVs durably isolated during follow-up, the estimates of RFA were the lowest of all energy sources at 71% (95% CI 69–73, 11 studies), but comparable with cryoballoon (79%, 95%CI 74–83, 3 studies). Higher durability percentages were reported in PVs ablated with laser-balloon (84%, 95%CI 78–89, one study) and PFA (87%, 95%CI 84–90, 2 studies). Conclusion: We observed no significant difference in the durability of the ablation lesions of the four evaluated energies after adjusting for procedural and baseline populational characteristics.

10 April 2024 in Heart Rhythm
Verified
Journal Article
Open access
FJFabian Jordan
Fabian Jordan
SKSven Knecht
Sven Knecht
CICorinne Isenegger
Corinne Isenegger
RARebecca Arnet
Rebecca Arnet
PKPhilipp Krisai
Philipp Krisai
PBPatrick Badertscher
Patrick Badertscher

26 March 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
PBPatrick Badertscher
Patrick Badertscher
SKSven Knecht
Sven Knecht
IZIvan Zeljković
Ivan Zeljković
CSChristian Sticherling
Christian Sticherling
CACarlo de Asmundis
Carlo de Asmundis
SBSerge Boveda
Serge Boveda
Conduction disorders such as left bundle branch block (LBBB) are common after transcatheter aortic valve implantation (TAVI). Consensus regarding a reasonable strategy to manage conduction disturbances after TAVI has been elusive. The European Heart Rhythm Association (EHRA) conducted a survey to capture contemporary clinical practice for conduction disorders after TAVI. A 25-item online questionnaire was developed and distributed among the EHRA electrophysiology (EP) research network centres. Of 117 respondents, 44% were affiliated with university hospitals. A standardized management protocol for advanced conduction disorders such as LBBB or atrioventricular block (AVB) after TAVI was available in 63% of participating centres. Telemetry after TAVI was chosen as the most frequent management strategy for patients with new-onset or pre-existing LBBB (79% and 70%, respectively). Duration of telemetry in patients with new-onset LBBB varied, with a 48-h period being the most frequently chosen, but almost half monitoring continued for at least 72 h. Similarly, in patients undergoing EP study due to new-onset LBBB, the HV interval cut-off point leading to pacemaker implantation was heterogeneous among European centres, although an HV >75 ms threshold was the most common. Conduction system pacing was chosen as a preferred approach by 3.7% of respondents for patients with LBBB and normal left ventricular ejection fraction (LVEF), and by 5.6% for patients with LBBB and reduced LVEF. This survey suggests some heterogenity in the management of conduction disorders after TAVI across European centres. The risk stratification strategies vary substantially. Conduction system pacing in patients with LBBB after TAVI is still underused.

9 May 2023 in Heart Rhythm
Verified
Journal Article
Closed access
PBPatrick Badertscher
Patrick Badertscher
SWSimon Weidlich
Simon Weidlich
TSTeodor Serban
Teodor Serban
PKPhilipp Krisai
Philipp Krisai
GVGian Voellmin
Gian Voellmin
MKMichael Kühne
Michael Kühne